Abstract
Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia (APL). In the present study, the concentrations of 8-hydroxy-2′-deoxyguanosine (8-OHdG) and arsenic compounds [(dimethylarsinic acid (DMA), monomethylarsonic acid (MMA), As(V), and As(III)] in urine of an APL patient were determined during ATO treatment. The concentrations of 8-OHdG, DMA, and MMA were increased, especially during the fi rst consolidation therapy. Signifi cant positive correlations were observed between concentrations of 8-OHdG and DMA, between concentrations of 8-OHdG and MMA, and between concentrations of 8-OHdG and the sum of arsenic compounds. The present study supports the idea that urinary 8-OHdG can be a marker for arsenic poisoning, when it is detected together with DMA and MMA. In addition, this study is the fi rst to show the relationship between 8-OHdG and levels of arsenic compounds in urine of an APL patient being treated with ATO.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
